Palvella Therapeutics, Inc. Common Stock
PVLAPalvella Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for dermatological and other dermatology-related diseases. It specializes in innovative topical treatments aimed at addressing unmet medical needs in skin-related conditions.
$102.38 +8.28 (8.81%)
Company News
Palvella Therapeutics Announces New QTORINâ„¢ Product Candidate, QTORINâ„¢ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies
Palvella Therapeutics introduced a new product candidate, QTORINâ„¢ pitavastatin, targeting disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease with no current FDA-approved therapies. The company plans to initiate a Phase 2 clinical trial in the second half of 2026.
